Drug intelligence / Profile preview

SGT-53 + temozolomide

Development stage: Discontinued
Lead developer: SynerGene Therapeutics
Modality: Small Molecules, Gene Therapies
Administration: Intravenous, Oral

Overview

SGT-53 + temozolomide is a combination therapy consisting of SGT-53, a tumor-targeting nanomedicine carrying the p53 gene, and temozolomide, an alkylating agent. SGT-53 works by restoring p53 function in tumor cells, which can boost anti-tumor immunity and enhance treatment effectiveness. Temozolomide is a prodrug that undergoes spontaneous conversion at physiological pH to form its active metabolite, which then alkylates DNA, causing damage that leads to cancer cell death. This combination was investigated for the treatment of recurrent glioblastoma.

Targets

DNATFRC (Transferrin Receptor)

Beyond the preview

Go deeper on SGT-53 + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGT-53 + temozolomide.

Explore the full profile